drugset / Trial / NCT01318733

Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01318733

Phase 3 Completed 449 enrolled Galderma R&D
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.

Timeline

Start
2011-03
Primary completion
2012-06
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.5 % Topical

Indications